

1 RESEARCH ARTICLE

2 Title: An Alternative Approach to Tablet Splitting and Grinding for Medication Administration

3

4 Rajneesh Taneja¹, Joseph Scarim², Poonam G Pande^{1*}, Anthony Scarim², Milap C Nahata³, Rita K
5 Jew⁴, Koteswara Inabathina¹

6

7 ¹Global Alliance for TB Drug Development (TB Alliance); ²JSAS Services Inc; ³Institute of
8 Therapeutic Innovations and Outcomes, Colleges of Pharmacy and Medicine, The Ohio State
9 University; ⁴Institute for Safe Medication Practices (ISMP)

10

11 *Correspondence

12 Poonam Pande, TB Alliance, 40 Wall Street, 24th Floor, New York, NY 10005

13 e-mail: poonam.pande-consultant@tballiance.org

14

15 Running head: Alternative method for suspending oral tablets

16

17 **Abstract**

18 **Purpose.** Tablet formulations fail to meet the needs of patients unable to swallow tablets such
19 as pediatric, elderly, and patients that must receive medications via feeding tubes. Our aim was
20 to develop and test a new, simple device (XTEMP-R™) and the methodology for converting
21 tablets into a homogeneous suspension for medication administration.

22 **Methods.** We developed a new device comprised of a flexible receptacle, a tight-fitting cap, and
23 a suction cup bottom to convert tablets into liquid preparations. TB treatment drugs, TBAJ-876
24 and TBI-223, were dispersed within the device utilizing water and commonly available
25 suspending vehicles. We investigated the effectiveness of the XTEMP-R device in dispersing
26 tablets. This was accomplished by visual observations, determining the fineness of dispersion,
27 and measuring the total drug recovery from the dispersions in XTEMP-R. We investigated the
28 accuracy and reproducibility of delivering aliquots from these suspensions by determining the
29 dose reproducibility upon suspension and upon redispersion after 24 hours. The effectiveness
30 of the device was also evaluated using commercially available tablets of acetaminophen,
31 amlodipine, glimepiride, metformin and valsartan.

32 **Results.** The suspensions were visually uniform without any large particles. The suspensions
33 passed through #18 sieve confirming that the particles were less than 1000 µm. Average total
34 dose recovery of three suspensions each was determined to be 101.3% and 99.2% for TBI-223
35 and TBAJ-876, respectively. Reproducibility from aliquots of 2 mL each were 98.9-99.7% for
36 three replicates of TBI-223 suspensions, and 102.6-103.2% for TBAJ-876 suspensions. Aliquots
37 tested after 24 hours confirmed uniform re-dispersibility.

38 **Conclusion.** We have demonstrated that XTEMP-R can be utilized to prepare homogeneous
39 suspensions can be prepared conveniently and efficiently in less than 10 minutes without any
40 drug loss. Aliquots for partial dose delivery can be withdrawn accurately. These findings
41 demonstrate that XTEMP-R can be used to accurately deliver doses of suspensions for patients
42 who cannot swallow tablets.

43

44 **Keywords:** aliquot, device, dosing, dysphagia, geriatric, pediatric, suspension

45

46

47 **Introduction**

48 Tablets remain the most common modality for oral dose administration of drugs. They
49 represent 28 of the top 30 prescription drugs in 2021 [1]. However, these formulations are not
50 suitable for some patients, especially young children, and those suffering from dysphagia.

51 Tablet administration is also a challenge for patients receiving enteral tube feeding [2]. If an
52 alternate oral formulation or route of administration is unavailable, manipulation of the dosage
53 form may be undertaken at the point of administration to provide the prescribed dose [3].

54 Manipulation involves physical alteration of the dosage form, including tablet splitting,
55 crushing, or grinding [4]. Dose adjustment is commonly achieved through tablet splitting,
56 whereas tablet crushing or grinding aid the swallowing or administration via an enteral feeding
57 tube [4].

58 Tablets are often pulverized (crushed or ground) with a mortar and pestle or other tablet
59 grinding device to facilitate administration [2,5]. However, this process is tedious and often
60 leads to the loss of the prescribed dose during preparation or administration [5]. In one study, it
61 was demonstrated that two rinses of the grinding devices with water were required to prevent
62 significant drug loss [5]. Screwcap crushers yield larger particles that are not suited for feeding
63 tube administration [4]. Also, some hazardous drugs may pose risks to caregivers preparing the
64 doses through the inhalation of generated powder containing the drug, or through contact with
65 skin, nose, and eyes [4].

66 Another common practice is tablet splitting [6,7]. It is used for many reasons including
67 delivering partial dose of the tablet, facilitating swallowing, or cost savings [8,9]. However, this

68 process raises the issues of drug loss, variation in dose uniformity, dose accuracy, and weight
69 uniformity between fragments [8]. Many tablets may not be suitable for splitting due to factors
70 such as hardness, size, shape, or absence of score line.

71 Steadman and colleagues [5] called for a device that minimizes drug loss and maximizes
72 medication delivery, i.e., a device that ensures a sealed environment for crushing followed by
73 mixing with a fluid and subsequent consumption from the same receptacle [5]. Salmon and
74 colleagues [2] expressed a need for a combined crushing and suspending device.

75 TBAJ-876 (US IND number 145,349) and TBI-223 (US IND Number 134,334) are two new
76 chemical entities under development as immediate-release tablets for the treatment of
77 tuberculosis. The tablets are available in 100 mg and 600 mg strengths, respectively. Dose
78 titration is required while conducting early clinical studies with these drugs. A liquid
79 formulation allows for the flexibility of aliquoting the desired dose in any fraction. The
80 alternative is to manufacture tablets in multiple strengths and choose a combination of
81 different strength tablets for the desired dose.

82 The objective of our work was to develop a device and methodology that enabled the
83 dispersion of TBI-223 and TBAJ-876 immediate-release tablets into a suspension in water
84 without the need for crushing or grinding in a contained environment. Further, a suspending
85 vehicle can be added to make it into a homogenous suspension that allows for accurate partial
86 dose delivery.

87 A new, simple device (XTEMP-R™) was developed, and the methodology for converting tablets
88 into a homogeneous suspension with this device is described in this paper. This device and

89 methodology can be used in any setting without crushing, grinding, or splitting the tablet
90 dosage form. Flavors and sweeteners may be added to the suspension for enhancing
91 palatability. Our work is not suited for modified release, delayed-release, or controlled-release
92 tablets and capsules. In this paper, the term tablet refers to immediate-release tablet. The term
93 dispersion refers to the disintegration of the tablet in a liquid media resulting in a suspension.
94 The terms dispersion and suspension convey the same meaning.
95 To demonstrate the utility of the XTEMP-R device, we investigated (a) time to disperse the
96 tablets, (b) fineness of dispersion, (c) total dose recovery, and (d) accuracy of delivering aliquots
97 from suspensions.
98 In addition to TBAJ-876 and TBI-223, the dispersibility of a few commercial tablets was also
99 conducted to verify the utility of this device.

100 **Materials and methods**

101 **Drugs and vehicles**

102 TBI-223 IR tablets, 600 mg, TB Alliance, lot 6767AU01, retest 11/2022
103 TBAJ-876 Tablets, 100 mg, TB Alliance, Batch 6767BG01, retest 10/2022
104 Valsartan tablets, USP, 320 mg (Macleods, lot EVI2032A, exp 07/2022)
105 Tylenol® (acetaminophen) extra-strength tablets, 500 mg (Johnson & Johnson, lot AFA111, exp
106 05/2025)
107 Metformin tablets, USP, 1000 mg (Ascend, lot 4200094A, exp 07/2023)
108 Glimepiride tablets, USP, 2 mg (Accord, lot P2005847, exp 10/2023)
109 Amlodipine tablets, USP, 2.5 mg, (Ascend, lot 21140696, exp 01/2024)
110 ORA-Blend®, Perrigo, lot 2077398, exp. 28 Feb 2025
111 ORA-Sweet®, Perrigo, lot 1346049, exp 31 July 2024
112 Water, Distilled, Culligan, R22075 06:56 L1 Best By 03/2023

113

114 **Chemicals**

115 Acetonitrile, HPLC, Spectrum Chemical Mfg. Corp, item HP412, lot 20020323

116 Water, HPLC, Concord Technology, 8003LC4000, lot 201222

117 Ammonium Acetate, Sigma-Aldrich, item 73594-25G-F, lot BCCH0197

118 Trifluoroacetic acid (TFA), HPLC grade, Sigma-Aldrich, item 91707-10X1ML, lot bccg6537

119 Sodium lauryl sulfate (SLS), Sigma-Aldrich, Reagent grade, item 436143, lot MKCQ6608

120

121 **Equipment and supplies**

122 HPLC: Hitachi L-2100 pump, Shimadzu SPD-10AVP detector, Shimadzu SCL-10AVP controller,
123 Shimadzu CTO-AVP column heater, SRI Instruments PeakSimple chromatography data system

124 Column: Zorbax Bonus RP (C18, 4.6 mm x 150 mm, 3.5 μ m)

125 Column: Waters Symmetry Shield RP-8 (4.6 mm x 150 mm, 5 μ m)

126 Syringe Filters, Tisch Scientific, Glass Fiber, Hydrophilic, 25mm, 1.0 μ m, PN SF14699, lot
127 170420083

128 Syringe Filters, PALL Life Sciences, PVDF, 13mm, 0.45 μ m, PN 4545, lot A10648946

129

130 **XTEMP-R™ device**

131 XTEMP-R comprises a flexible receptacle, a tight-fitting cap, and a suction cup bottom (Fig 1). It

132 is a soft walled device manufactured with biocompatible, low hardness HCR (high-consistency

133 silicone rubber) sourced from Wacker, Germany. The construction material, platinum-cured

134 silicone, complies with FDA 21 CFR 177.2600, German Bfr XV, France Arrete Du 25, ROHS,

135 TSE/BSE free, USP Class VI Certification, and ISO 10993 Certification. These devices are

136 produced by a compression molding process (Ami Polymers Pvt. Ltd., India) in a class 10000

137 cleanroom. The height of the XTEMP-R device is 140 mm, the internal diameter is 22 mm, and

138 the capacity is approximately 40 mL. The device has volume markings on the outside at 5-mL

139 intervals starting at 15 mL. This device is resistant to extremes of environments and
140 temperatures and is designed to be leak-resistant and is easy to squeeze between the fingers
141 for manual dispersion of the tablets.

142 **Fig 1. X-TEMP-R™ Device.**

143

144 **Preparation of suspensions from tablets using XTEMP-R**

145 The general preparation technique is displayed in Fig 2 with preparation of TBI-223 suspension
146 as an example.

147 **Fig 2. Preparation of TBI-223 Suspension from Tablets.**

148

149 **TBAJ-876**

150 One tablet of TBAJ-876 100 mg was added to the XTEMP-R followed by 5 mL of water. The
151 device was capped and swirled for 5 seconds and left undisturbed for 5 minutes. Then the
152 tablet was manually massaged in the XTEMP-R for 2 minutes. ORA-Sweet suspending vehicle,
153 19.5 mL was added to the dispersion in the XTEMP-R make a final volume that coincided with
154 the 25-mL mark on the device and a final concentration of 4 mg/mL. The device was capped
155 and shaken 25 times to mix thoroughly. For redispersion, the suspension was shaken 25 times.

156 **TBI-223**

157 One tablet of TBI-223 600 mg was added to the XTEMP-R followed by 5 mL of water. The device
158 was capped and swirled for 5 seconds and left undisturbed for 5 minutes. Then the tablet was
159 manually massaged in the XTEMP-R for 2 minutes. ORA-Blend suspending vehicle, 9.4 mL was
160 added to the dispersion in the XTEMP-R to make a final volume that coincided with the 15-mL

161 mark on the device and a final concentration of 40 mg/mL. The device was capped and shaken
162 25 times to mix thoroughly. For redispersion, the suspension was shaken 25 times.

163 **Evaluation of suspensions prepared in XTEMP-R**

164 **Visual observation**

165 **TBAJ-876 and TBI-223**

166 The prepared suspensions of TBAJ-876 and of TBI-223 were shaken, and then an aliquot of each
167 was poured onto a watch glass. The suspensions were examined for color, uniformity, and
168 presence of large particles, agglomerates, or clumps.

169 **Fineness of dispersion**

170 Dispersions of tablets in water prepared in the XTEMP-R device were tested for fineness of
171 dispersion.

172 **TBAJ-876 and TBI-223**

173 One tablet was added to the XTEMP-R followed by 5 mL of water. The tablet was allowed to
174 soak for 5 minutes, followed by 2 minutes of massaging in the XTEMP-R. The dispersion was
175 poured through a #18 sieve (1000 μm opening) with a pan at the bottom for collecting the
176 dispersion. This test was performed in triplicate by each of two analysts.

177 **Total dose recovery from tablet dispersion in XTEMP-R**

178 **TBAJ-876**

179 The prepared 25 mL suspension in the XTEMP-R device was shaken 25 times and transferred to
180 a 250 mL volumetric flask. The device was rinsed with 15 mL of water and the rinse was added
181 to the volumetric flask with the suspension. This stock solution was diluted to volume with 1:1
182 acetonitrile:water. A sample of this stock solution was further diluted with diluent (Table 1) to a

183 concentration of 0.04 mg/mL. An aliquot of this diluted sample was filtered and analyzed by
184 HPLC as described under *Analytical test methods* below. The recovery was tested on three
185 preparations.

186 **TBI-223**

187 The prepared 15 mL suspension in the XTEMP-R device was shaken 25 times and transferred to
188 a 250 mL volumetric flask. The device was rinsed with 15 mL of water and the rinse was added
189 to the volumetric flask with the suspension. A volume of 30 mL of acetonitrile was added to the
190 flask and mixed. This stock solution was diluted with diluent (Table 1) to volume. A sample of
191 this stock was further diluted with diluent to a concentration of 0.05 mg/mL. An aliquot of this
192 sample was filtered and analyzed by HPLC as described under *Analytical test methods* below.
193 The recovery was tested on three preparations.

194 **Dose reproducibility of aliquots of tablet dispersion in XTEMP-R**

195 A general technique for withdrawal of aliquots for partial doses is represented in Fig 3.

196 **Fig 3. Withdrawal of an Aliquot from XTEMP-R for Partial Dose of TBI-223 Suspension.**

197

198 **TBAJ-876**

199 Prior to withdrawal of the dose aliquot, a syringe adapter was attached to the opening of
200 XTEMP-R and the device was capped. The prepared 25 mL suspension in the XTEMP-R device
201 was shaken 25 times and a 3-mL oral syringe was attached to the syringe adapter. A 2-mL
202 aliquot was removed for an 8-mg dose. The dose reproducibility was tested on three 2-mL
203 aliquots withdrawn from the same preparation. For each withdrawal of the aliquot, the capped
204 device was shaken to simulate the procedure that would be followed by the patient or

205 caregiver. This was repeated on three different preparations. Each 8-mg dose was diluted with
206 diluent to a concentration of 0.04 mg/mL, filtered, and analyzed by HPLC. The remaining
207 suspension in the XTEMP-R was left undisturbed on the bench for about 24 hours. The
208 preparations were redispersed by shaking and one aliquot from each preparation was
209 withdrawn and tested.

210 **TBI-223**

211 Prior to withdrawal of the dose aliquot, a syringe adapter was fitted on to the device and the
212 device was capped. The prepared 15 mL suspension in the XTEMP-R device was shaken 25
213 times and a 3-mL oral syringe was attached to the syringe adapter. A 2-mL aliquot was removed
214 for an 80-mg dose. The dose reproducibility was tested on three 2-mL aliquots withdrawn from
215 the same preparation. For each withdrawal of the aliquot, the capped device was shaken to
216 simulate the procedure that would be followed by the patient or caregiver. This was repeated
217 on three different preparations. Each dose withdrawn was transferred into a 100-mL volumetric
218 flask. Acetonitrile 2 mL was added to the flask and swirled to mix the sample with the solvent.
219 The mixture in the flask was then diluted with diluent to volume. An aliquot of 3 mL of this
220 stock sample preparation was diluted to 50 mL to a concentration of 0.05 mg/mL. An aliquot of
221 this sample preparation was filtered and analyzed by HPLC. The remaining suspensions in the
222 XTEMP-R were left undisturbed on the bench for about 24 hours and an aliquot from each
223 preparation was tested after redispersing.

224 **Analytical test methods for TBAJ-876 and TBI-223**

225 Stability-indicating validated HPLC methods were used for the potency testing of TBI-223 and
226 TBAJ-876 suspensions. Details of the HPLC methods are provided in Table 1.

227 **Table 1. Details of Stability-Indicating HPLC Methods for Potency Testing of TBI-223 and TBAJ-**
 228 **876 Suspensions.**

Parameter	Details	
	TBI-223	TBAJ-876
Instrument	Hitachi L-2100 pump, Shimadzu SPD-10AVP detector, Shimadzu SCL-10AVP controller, Shimadzu CTO-AVP column heater, SRI Instruments PeakSimple chromatography data system	
Column	Zorbax Bonus RP (C18, 4.6 mm x 150 mm, 3.5µm)	Waters Symmetry Shield RP-8 (4.6 mm x 150 mm, 5µm)
Wavelength	258 nm	236 nm
Column Temp.	30 °C	40 °C
Flow Rate	0.8 mL/min	2.0 mL/min
Injection Volume	10 µL	5 µL
Syringe filter	1.0 µm glass fiber filter	0.45 µm PVDF syringe filter
Standard and sample Concentration	0.05 mg/mL	0.04 mg/mL
Mobile Phase	Mobile Phase-A: 0.05% TFA in water Mobile Phase-B: 0.05% TFA in Acetonitrile	0.01M Ammonium acetate: Acetonitrile (1:3)
Diluent	0.2% SLS in Water:Acetonitrile (1:1)	Water:Acetonitrile (1:4)
Run Time	8 minutes (Gradient: 0.0-2.0 mins: A:64% and B:36%; 2.0-4.5 mins: A:64% and B:36% to A:46% and B:54%; 4.6-8.0 mins: A:64% and B:36%)	7 minutes (Isocratic)
Peak retention time	About 3.6 minutes	About 4.4 minutes
Integration	Peak area method using PeakSimple data acquisition system	Peak area method using PeakSimple data acquisition system

229

230 **TBAJ-876 quantification method validation**

231 The method was validated for specificity (placebo interference and forced degradation),

232 linearity, filter study, precision (system suitability and repeatability), and accuracy according to

233 International Conference on Harmonization (ICH) guidelines [10]. Specificity was assessed to

234 verify the absence of interference from tablet excipients, and suspension matrix and to

235 establish the analyte peak does not interfere with the possible degradants of the forced
236 degradation of samples. Seven-point calibration curve was constructed with standard solutions
237 in the range of 50% (20 µg/mL) to 150% (60 µg/mL) of standard concentration i.e., 40 µg/mL.

238 **TBI-223 quantification method validation**

239 The method was validated for specificity (placebo interference and forced degradation),
240 linearity, filter study, precision (system suitability and repeatability), and accuracy according to
241 ICH guidelines. Specificity was assessed to verify the absence of interference from tablet
242 excipients, and suspension matrix and to establish the analyte peak does not interfere with the
243 possible degradants of the forced degradation of samples. Five-point calibration curve was
244 constructed with standard solutions in the range of 50% (25 µg/mL) to 150% (75 µg/mL) of
245 standard concentration i.e., 50 µg/mL.

246 **Dispersions of commercial tablets prepared in XTEMP-R**

247 We tested five different commercially available tablets to determine effectiveness of the
248 XTEMP-R device in producing a fine dispersion that passed through a #18 sieve (1000 µm
249 opening). The commercial tablets were selected to represent small and large tablets.
250 Manufacturer details, composition, tablet weight and drug content of the commercial tablets
251 tested are provided in Table 2. Metformin tablets were included for evaluation to challenge the
252 dispersing functionality of the XTEMP-R device, as they represent high dose, and high drug load
253 tablets with a high drug to excipient ratio.

254 We tested the dispersibility of these commercial tablets by using the same methodology of
255 soaking them in water for 5 minutes and massaging for 2 minutes, similar to the TBAJ-876 and
256 TBI-223 tablets. The suspensions were tested for fineness of dispersion.

257 We also tested these commercial tablets for the shortest massaging time that could accomplish
258 dispersion for fineness. One tablet was added to the XTEMP-R followed by 5 mL of water and
259 massaged in the XTEMP-R device until the analyst felt that the tablet was completely dispersed,
260 and the time was recorded. The suspension was poured through a #18 sieve (1000 μm opening)
261 with a pan at the bottom for collecting the dispersion. This test was performed in triplicate by
262 each of two analysts.

263

264 **Table 2. Commercial Tablets Tested for Dispersion Times for Fineness of Dispersion.**

Product	Manufacturer	NDC	Inactive Ingredients	Tablet Weight (mg)	% Drug in Tablet
Valsartan 320 mg	MacLeods	33342-065-10	Colloidal silicon dioxide, crospovidone*, hypromellose, iron oxides (yellow, black and/or red), microcrystalline cellulose, magnesium stearate, polyethylene glycol, talc and titanium dioxide	1030	31.1
Acetaminophen 500 mg (Tylenol®)	McNeil	50580-449-96	Carnauba wax, corn starch, FD&C red no. 40 aluminum lake, hypromellose, magnesium stearate, modified starch, polyethylene glycol, powdered cellulose, pregelatinized starch, propylene glycol, shellac, sodium starch glycolate*, titanium dioxide	610	82.0
Glimepiride 2 mg	Accord	16729-002-01	Lactose monohydrate, sodium starch glycolate*, povidone, and magnesium stearate. Ferric oxide yellow and FD & C blue #2 aluminum lake	170	1.2
Amlodipine 2.5 mg	Ascend	67877-197-90	Microcrystalline cellulose, dibasic calcium phosphate anhydrous, sodium starch glycolate*, colloidal silicon dioxide and magnesium stearate	100	2.5
Metformin 1000 mg	Ascend	67877-563-01	Povidone (K-30), povidone (K-90), pregelatinized starch*, and magnesium stearate. Coating: artificial blackberry flavor, hypromellose and polyethylene glycol.	1080	92.6

265 *disintegrant

266 **Results**

267 **Preparation of suspensions from tablets using XTEMP-R**

268 **TBAJ-876 and TBI-223**

269 The suspension preparation technique for the two tablets, TBAJ-876 and TBI-223, was found to
270 be simple, efficient and could be performed well in this closed system. The suspensions were
271 prepared in less than 10 minutes without any complicated, tedious, or messy steps. The details
272 of the suspension evaluation are provided below.

273 **Evaluation of suspensions prepared in XTEMP-R**

274 **Visual observation**

275 **TBAJ-876 and TBI-223**

276 Fig 4 shows the visual appearance of the suspensions of the two drugs, TBI-223 and TBAJ-876.
277 Both suspensions had uniform appearance and the particles were observed to be
278 homogeneously dispersed. TBI-223 suspension was observed to be milky white, opaque, and
279 uniform when light was shown from below the watch glass containing the suspension. TBAJ-876
280 suspension was translucent with distinct particles visible and uniformly dispersed. The
281 appearance of the suspension as translucent or opaque is dependent on the ingredients and
282 composition of the tablets and the dispersion vehicle.

283 **Fig 4. Visual Observation of Suspensions Prepared in XTEMP-R.** (a) Appearance of TBAJ-876
284 suspension, (b) TBAJ-876 suspension in XTEMP-R device, (c) Appearance of TBI-223 suspension,
285 (d) TBI-223 suspension in XTEMP-R device.

286

287 **Fineness of dispersion**

288 **TBAJ-876 and TBI-223**

289 The dispersions prepared with 5-minute soaking and 2-minute massaging times in the XTEMP-R
290 device passed through the #18 sieve. No particles were retained indicating that all particles
291 were below 1000 μm and dispersed particles were not forming aggregates or agglomerates.

292 **Total dose recovery from tablet dispersion in XTEMP-R**

293 **TBAJ-876 and TBI-223**

294 The total dose recovered from the triplicate preparations of TBAJ-876 and TBI-223 in XTEMP-R
295 are presented in Table 3. The recovery of TBAJ-876 from three distinct preparations in XTEMP-R
296 ranged from 98.8-100.0% with an average recovery of 99.2%. The recovery of TBI-223 from
297 three distinct preparations in XTEMP-R ranged from 100.4-102.9% with an average recovery of
298 101.3%. These ranges include inherent tablet-to-tablet content variability as well as analytical
299 variability.

300

301 **Table 3. Recovery of TBI-223 and TBAJ-876 from Suspensions Prepared in XTEMP-R.**

Tablet	Suspending Agent	Dispersion time (minutes)	Preparation	Total Recovered (%) from entire contents in device
TBAJ-876	Water + ORA-Sweet	5 minutes soak+2 minutes massage	1	98.8
			2	100.0
			3	99.0
			Average (RSD)	99.2 (0.64)
TBI-223	Water + ORA-Blend	5 minutes soak+2 minutes massage	1	100.4
			2	100.5
			3	102.9
			Average (RSD)	101.3 (1.4)

302 RSD = relative standard deviation

303 **Dose reproducibility of aliquots of tablet dispersion in XTEMP-R**

304 **TBAJ-876 and TBI-223**

305 The results for dose reproducibility are provided in Table 4. Average potency of three
306 suspensions from three replicate aliquots of 2-mL from each suspension were found to be
307 98.9-99.7% for TBI-223 suspensions, and 102.6-103.2% for TBAJ-876 suspensions. The potency
308 of an additional aliquot withdrawn after redispersing after 24 hours from each of the three
309 suspensions was found to be 96.0-100.3% for TBAJ-876 suspensions and 99.3-100.3% for
310 TBI-223 suspensions.

311

312 **Table 4. Dose Reproducibility of Aliquots Withdrawn from TBAJ-876 and TBI-223 Suspensions.**

Tablet	Suspending Agent	Aliquot	Theoretical dose dispensed (%)		
			Preparation 1	Preparation 2	Preparation 3
TBAJ-876	Water + ORA-Sweet	Day 0	99.2	101.2	102.2
			104.5	102.5	104.3
			105.7	104.2	103.0
		Average (RSD)	103.1 (3.44)	102.6 (1.44)	103.2 (0.99)
		Day 1	96.0	100.3	98.2
TBI-223	Water + ORA-Blend	Day 0	99.4	98.8	99.9
			98.5	98.9	99.8
			99.3	98.9	99.5
		Average (RSD)	99.1 (0.5)	98.9 (0.1)	99.7 (0.2)
		Day 1	100.3	99.3	100.2

313 RSD = relative standard deviation

314 **TBAJ-876 tablets test method validation**

315 The seven-point calibration curve in the range of 20 µg/mL to 60 µg/mL was linear with a high
316 correlation coefficient (r) of 1.000. For both standard and sample tests, % RSD for inter- and
317 intra-day precision were well below 2%, and mean recovery was well within the range of 98% to
318 102%.

319 **TBI-223 tablets test method validation**

320 The five-point calibration curve in the range of 25 µg/mL to 75 µg/mL was linear with a high
321 correlation coefficient (r) of 1.000. For both standard and sample tests, % RSD for precision
322 were well below 2%, and mean recovery was well within the range of 98% to 102%.

323 **Dispersions of commercial tablets prepared in XTEMP-R**

324 The suspensions prepared with 5-minute soaking and 2-minute massaging times in the
325 XTEMP-R device passed through the #18 sieve. No particles were retained indicating that all
326 particles were below 1000 µm and dispersed particles were not forming aggregates or
327 agglomerates.

328 The earliest dispersion times for all commercial tablets tested ranged from 1-3 minutes except
329 for metformin which did not disintegrate within the time tested (10 minutes soaking and 5
330 minutes massaging). The dispersion times presented in Table 5 represent the dispersion time
331 for the suspensions prepared by two independent analysts that passed the fineness of
332 dispersion test.

333 The drug content (labelled dose of the drug in total tablet weight) and disintegrant in each
334 tablet formulation are provided in Table 2. Except for metformin, all other tablet formulations

335 contained superdisintegrants. Valsartan, acetaminophen, and metformin had 31, 82, and 93%
336 of drug load, respectively. Glimepiride and amlodipine contained 1.2 and 2.5% of drug load,
337 respectively.

338 **Table 5. Dispersion Times of Commercial Tablets.**

Tablet	Dispersion Time (min) in X-TEMP-R
Valsartan	1.5
Acetaminophen	3
Glimepiride	3
Amlodipine	1
Metformin	>10*

339 * Did not disperse in time tested (10 minutes soaking and 5-minute massaging)

340 Discussion

341 Tablet splitting, crushing, and grinding is a common practice for medication administration. The
342 necessity for splitting or crushing tablets arises from the need to administer drug doses other
343 than that are available in tablet formulations, as well as facilitate the swallowing of tablets [11].
344 There have been some challenges identified with both, tablet splitting and tablet pulverization.
345 Large deviations of dose can occur due to unequal fragments of split tablets or weight
346 differences due to loss of powdered or chipped material resulting from the splitting process [9].
347 Tablet crushing can result in significant drug loss [5]. Some crushing devices yield large particles
348 that cannot be administered via a feeding tube [4]. Aerosolized powder during crushing and
349 grinding can be an environmental [2] and health hazard.

350 This paper describes a procedure for converting tablets into a suspension: (1) that is simple and
351 reproducible; (2) where tablet disintegration and preparation of suspension is performed within

352 the same device; (3) in a contained environment; (4) that enables measurement and
353 withdrawal of any required dose with accuracy; (5) with small particle size that permits
354 administration through feeding tubes; and (6) where consumption is possible from the same
355 receptacle.

356 XTEMP-R is a simple mechanical device designed to facilitate and expedite the disintegration
357 and dispersion of tablets in a small volume (<10 mL) of water. This device is constructed with
358 low hardness silicone, making it pliable yet durable. It can be gently squeezed by fingers to
359 facilitate the dispersion of the tablet. This squeezing and massaging action facilitated the
360 interaction of water with the superdisintegrants present in the tablet, thus promoting its
361 dispersion. These ingredients are routinely included in the tablet formulations to aid in the
362 break-up of the compacted mass.

363 The disintegration and suspension of tablets in the XTEMP-R device occurs in the same
364 container in a closed environment. Therefore, there is minimal risk of any drug loss during the
365 preparation. The XTEMP-R container does not have any cutting or grinding parts. It is also safer
366 for caregivers to prepare the suspension with XTEMP-R since there is minimal contact with the
367 drug either by touch or by inhalation of drug powder that may get aerosolized during
368 pulverization.

369 Both TBAJ-876 and TBI-223 tablets are investigational drugs under IND applications with
370 established specifications and content uniformity standards. As demonstrated by the results,
371 TBAJ-876 and TBI-223 tablets could be dispersed homogeneously in water and suspending
372 vehicle within 10 minutes. Accurate aliquots could be withdrawn reproducibly from the device

373 immediately after the preparation and 24 hours later. We withdrew aliquots from each
374 preparation sequentially after preparation and on the following day after redispersing by
375 shaking. This closely simulates what would occur in the pharmacy, at the patient's home or at
376 the clinical investigation site. The partial doses withdrawn for the suspension were uniform and
377 stable as they could be redispersed reproducibly after 24 hours. It was not our intent to
378 prepare suspensions for long term storage.

379 Fineness of dispersion was one of the quality criteria. The suspensions were tested by passing
380 them through a #18 sieve (1000 μm aperture). Our objective was to ensure that no particle
381 agglomerates were present in the suspension and that the largest particles in the suspension
382 could be suspended in commonly available suspending vehicles. Bowles and colleagues [13]
383 have demonstrated that particles up to 1000 μm can be successfully suspended with the aid of
384 commonly used suspending vehicles.

385 Drug loss is one of the challenges when the tablets are pulverized before dispersing in a
386 suspension. Drug powder tend to stick to the walls of the container such as a mortar and pestle.
387 Thong and colleagues [5] have recommended two rinses of the tablet crushing devices to
388 ensure minimum drug loss. Close to 100% of active drug from all three suspensions of TBAJ-876
389 and TBI-223 prepared by the XTEMP-R device was recovered. The devices were only rinsed once
390 with 15 mL of water for each preparation. The total dose could be ingested directly from the
391 device avoiding a transfer to a dispensing container. This methodology offers an alternative
392 dose administration option for patients suffering from dysphagia.

393 We have also investigated the applicability of this device for some commercial tablets. Except
394 for metformin, the tablets could be dispersed by soaking for 5 minutes and massaging for 2
395 minutes. For some products, the dispersion could be faster by just massaging for 1-3 minutes.
396 The metformin tablets had a high drug load with just about 8% excipients and did not contain
397 any superdisintegrants. Desai and colleagues [14] studied metformin formulation with minimal
398 excipients and concluded that even for a highly soluble drug, a superdisintegrant was needed in
399 the formulation to change the dissolution mechanism from erosion-diffusion to disintegration.
400 Masum and colleagues [15] formulated metformin tablets with different disintegrants and
401 found that the wetting time, dispersion time and the disintegration time of metformin tablets
402 were governed by the type and quantity of the superdisintegrants. In the XTEMP-R device, the
403 volume of the dispersing vehicle (5-7 mL water) and massaging are not sufficient to have
404 effective erosion-diffusion for the tablet to dissolve or disperse the metformin tablet.
405 Therefore, the use of the XTEMP-R device may be limited for tablets that depend primarily on
406 solubilization for dissolution and do not contain effective disintegrants. These observations
407 corroborate our assumption that XTEMP-R promotes the interaction between water and tablet
408 formulations. The ingredients of each tablet formulation can be found in the product
409 prescribing information.

410 The lack of child-friendly formulations leaves 40% of the world population at increased risk for
411 preventable adverse events, suboptimal dosing, noncompliance, and lack of access to new
412 medicines [16]. In some instances, the caregiver is required to administer a quarter of a tablet
413 to a neonate. XTEMP-R device may offer an alternative for accurate dosing in this patient
414 population. Of course, appropriate development and analytical work will have to be performed.

415 Fortunately, several publications [17,18] describing the compatibility of drugs that lack pediatric
416 formulations with commonly available suspending agents and with established storage
417 conditions and shelf life are available.

418 **Limitations**

419 XTEMP-R device worked well with the tablets containing superdisintegrants in the formulation.

420 This device, however, may not work well with certain large tablets with a high drug-to-excipient
421 ratio and/or tablets not containing effective disintegrants in the formulation. This will have to
422 be tested on a case-by-case basis.

423 This device does not offer protection from light. Photosensitive drug preparations should be
424 stored in the device with added protection from light.

425 The silicone material of the XTEMP-R device may be stained from a colored drug dispersion.

426 Therefore, it is recommended that a dedicated device should be used for colored drugs such as
427 clofazimine.

428 Dose preparation may be challenging for patients that are unable to massage the tablet in the
429 device. XTEMP-E™, another version of XTEMP-R is equipped with an electronic mechanism for
430 mixing. XTEMP-E will be presented in a subsequent publication.

431 The utility of this device and methodology for suspending any tablet formulation has to be
432 supported by appropriate development and analytical work. As exemplified by the work
433 conducted for TBAJ-876 and TBI-223 in this paper, similar rigor is recommended for any other
434 drug that will utilize XTEMP-R for suspension.

435 Conclusion

436 We have demonstrated that the new XTEMP-R device can be utilized for aliquoting partial
437 doses of TBAJ-876 and TBI-223 immediate release tablets. Homogeneous suspensions could be
438 prepared conveniently, safely, and expeditiously without any significant loss. Further, this
439 device has the potential to offer an alternative for dosing patients who cannot ingest
440 immediate release tablets. This could be beneficial to pediatric and elderly patients, intubated
441 patients, and patients with dysphagia. Additional work is required to establish the utility of the
442 device for other immediate release tablets.

443 Acknowledgements

444 The authors are grateful for the funding provided by TB Alliance.

445 References

- 446 1. Ranked: The most prescribed drugs in the U.S. by Omri Wallach, Graphics/Design:
447 Amy Realey; 2021 Nov 1; [https://www.visualcapitalist.com/ranked-the-most-](https://www.visualcapitalist.com/ranked-the-most-prescribed-drugs-in-the-u-s/)
448 [prescribed-drugs-in-the-u-s/](https://www.visualcapitalist.com/ranked-the-most-prescribed-drugs-in-the-u-s/). (accessed 2021 Dec 12).
- 449 2. Damien Salmon, Elisa Pont, H el ene Chevallard, Elhadji Diouf, Mamadou-Lamine Tall,
450 Christine Pivot, Fabrice Pirot, Pharmaceutical and safety considerations of tablet
451 crushing in patients undergoing enteral intubation, International Journal of
452 Pharmaceutics, Volume 443, Issues 1–2, 2013, Pages 146-153, ISSN 0378-5173,
453 <https://doi.org/10.1016/j.ijpharm.2012.12.038>.
- 454 3. Diana A. van Riet Nales, Piotr Kozarewicz, Siri Wang, Agnes Saint-Raymond, Jean-
455 Louis Robert, Comments on the EMA draft guideline: Final steps towards a
456 harmonized view between regulators and industry, International Journal of
457 Pharmaceutics, Volume 457, Issue 1, 2013, Pages 337-339, ISSN 0378-5173,
458 <https://doi.org/10.1016/j.ijpharm.2013.08.060>.
- 459 4. Woerdenbag HJ, Visser JC, Leferink Op Reinink MPAM, van Orsoy RR, Eissens AC,
460 Hagedoorn P, Dijkstra H, Allersma DP, Ng SW, Smeets OSNM, Frijlink HW.
461 Performance of Tablet Splitters, Crushers, and Grinders in Relation to Personalised
462 Medication with Tablets. Pharmaceutics. 2022 Jan 28;14(2):320. doi:
463 10.3390/pharmaceutics14020320. PMID: 35214052; PMCID: PMC8878961.
- 464 5. Thong MY, Manrique YJ, Steadman KJ (2018) Drug loss while crushing tablets:
465 Comparison of 24 tablet crushing devices. PLOS ONE 13(3): e0193683.

- 466 <https://doi.org/10.1371/journal.pone.0193683>; PMID: 29494695; PMCID:
467 PMC5832315.
- 468 6. Helmy SA. Tablet splitting: is it worthwhile? Analysis of drug content and weight
469 uniformity for half tablets of 16 commonly used medications in the outpatient
470 setting. *J Manag Care Spec Pharm*. 2015 Jan;21(1):76-86. doi:
471 10.18553/jmcp.2015.21.1.76. PMID: 25562775.
- 472 7. Starling, Flavio & Camargos, Einstein & Ferreira, Felipe & Polo, Marco & Freitas,
473 Marco Polo & Costa, Reinaldo & Medeiros-Souza, Patricia. (2019). UNAVAILABILITY
474 OF APPROPRIATE DOSES AND NEED FOR TABLET SPLITTING OF PSYCHOTROPIC
475 DRUGS BY GERIATRIC PATIENTS Indisponibilidade de doses apropriadas e
476 necessidade de fracionamento de medicamentos psicotr3picos por pacientes
477 geri3tricos. *Geriatr Gerontol Aging*. 2019;13(3):126-32.
- 478 8. Freeman MK, White W, Iranikhah M. Tablet splitting: a review of weight and content
479 uniformity. *Consult Pharm*. 2012 May;27(5):341-52. doi: 10.4140/TCP.n.2012.341.
480 PMID: 22591978.
- 481 9. Verrue C, Mehuis E, Boussery K, Remon JP, Petrovic M. Tablet-splitting: a common
482 yet not so innocent practice. *J Adv Nurs*. 2011 Jan;67(1):26-32. doi: 10.1111/j.1365-
483 2648.2010.05477.x. PMID: 21158902.
- 484 10. International Conference on Harmonisation of Technical Requirements for
485 Registration of Pharmaceuticals for Human Use (ICH). Guidance for Industry, Q2B
486 Validation of Analytical Procedures: Methodology. 1996, ICH-Quality final guidance
487 FDA issue date 1997. [https://www.fda.gov/regulatory-information/search-fda-
488 guidance-documents/q2b-validation-analytical-procedures-methodology](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q2b-validation-analytical-procedures-methodology)
- 489 11. Pahwa, R, Gupta, N. Superdisintegrants in the development of orally disintegrating
490 tablets: a review. *Int J Pharm Sci Res* 2010; 2: 2767-80.
491 [http://dx.doi.org/10.13040/IJPSR.0975-8232.2\(11\).2767-80](http://dx.doi.org/10.13040/IJPSR.0975-8232.2(11).2767-80)
- 492 12. Markl D, Zeitler JA. A Review of Disintegration Mechanisms and Measurement
493 Techniques. *Pharm Res*. 2017 May;34(5):890-917. doi: 10.1007/s11095-017-2129-z.
494 Epub 2017 Mar 1. PMID: 28251425; PMCID: PMC5382187.
- 495 13. Bowles, A., Ernest, T., Clapham, D., & Tuleu, C. (2010, November). Evaluation of the
496 rheological and suspending properties of commonly used oral suspending vehicles.
497 Poster presented at International Pharmaceutical Federation World
498 Congress/Annual Meeting American Association of Pharmaceutical Scientists, New
499 Orleans, USA
- 500 14. Desai D, Wong B, Huang Y, Tang D, Hemenway J, Paruchuri S, Guo H, Hsieh D,
501 Timmins P. Influence of dissolution media pH and USP1 basket speed on erosion and
502 disintegration characteristics of immediate release metformin hydrochloride tablets.
503 *Pharm Dev Technol*. 2015;20(5):540-5. doi: 10.3109/10837450.2014.892132. Epub
504 2014 Mar 12. PMID: 24621340.
- 505 15. Masum MA et al., Effect of Superdisintegrants on Physical Attribute and Release
506 Profile of Metformin HCl Immediate Release Tablets. *American Journal of
507 PharmTech Research* 2013; 3(1):1025-1036. ISSN:2249-3387

- 508 16. Milne CP, Bruss JB. The economics of pediatric formulation development for off-
509 patent drugs. *Clin Ther*. 2008 Nov;30(11):2133-45. doi:
510 10.1016/j.clinthera.2008.11.019. PMID: 19108801.
- 511 17. Jew RK, Soo-Hoo W, Erush SC, *et al*. Extemporaneous formulations for pediatric,
512 geriatric, and special needs patients, 3rd ed. ASHP, 2016.
- 513 18. Nahata, MC, Pai, VB. Pediatric drug formulations, 7th ed. Harvey Whitney Books
514 Company, 2018.

516 **Supporting Information**

517 Link to video for suspension preparation methodology

518 <https://www.dropbox.com/sh/t0bj2o6ivjuh8l3/AAAZe3mRxc1HImGIbpoFDUUua?dl=0>

519 **S1 Fig. Representative chromatograms of TBAJ-876 analysis** (a) Standard 1, (b) Diluent blank,
520 (c) Day 0 aliquot for dose reproducibility, (d) Day 0 suspension matrix blank (diluent + ORA-
521 Sweet), (e) Day 1 aliquot for dose reproducibility, (f) Day 1 suspension matrix blank (diluent +
522 ORA-Sweet), (g) Standard 2, (h) Total dose recovery

523 **S2 Fig. Representative chromatograms of TBI-223 analysis** (a) Standard 1, (b) Diluent blank, (c)
524 Day 0 aliquot for dose reproducibility, (d) Day 0 suspension matrix blank (diluent + ORA-Blend),
525 (e) Day 1 aliquot for dose reproducibility, (f) Day 1 suspension matrix blank (diluent + ORA-
526 Blend), (g) Standard 2, (h) Total dose recovery

527

Author contributions

Rajneesh Taneja conceptualized and designed the device and experiments

Joseph Scarim conceptualized and designed the device and experiments


Poonam G Pande designed and coordinated the testing, corresponding author

Anthony Scarim conducted the analytical work

Milap C Nahata consulted on the utility of the device

Rita K Jew consulted on the utility of the device

Koteswara Inabathina coordinated the device manufacture




medRxiv preprint doi: <https://doi.org/10.1101/2022.08.26.22279282>; this version posted August 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Figure 1

medRxiv preprint doi: <https://doi.org/10.1101/2022.08.26.22279282>; this version posted August 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).




Figure 2



medRxiv preprint doi: <https://doi.org/10.1101/2022.08.26.22279282>; this version posted August 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).


Figure 3



(a)



(b)



(c)



(d)

medRxiv preprint doi: <https://doi.org/10.1101/2022.08.26.22279282>; this version posted August 30, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](#).